50533-97-6

Basic information

• Product Name: N,N-Dimethylpiperidin-4-amine
• Synonyms: N,N-DIMETHYLPIPERIDIN-4-AMINE;AKOS BB-9178;4-(N,N-DIMETHYLAMINO)PIPERIDINE;4-DIMETHYLAMINO-PIPERIDINE;DIMETHYL-PIPERIDIN-4-YL-AMINE;CHEMBRDG-BB 4018153;4-(Dimethylamino)piperidine,98%;4-DIMETHYLAMINO-PIPERIDINE 98%
• CAS NO: 50533-97-6
• Molecular Formula: C₇H₁₆N₂
• Molecular Weight: 128.22
• EINECS: 256-617-2
• Product Categories: Amines and Anilines;Heterocycles;Piperidine
• Mol File: 50533-97-6.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 187°C
• Flash Point: 187°C
• Appearance: clear slightly yellow liquid
• Density: 0.91 g/cm³
• Vapor Pressure: 0.929mmHg at 25°C
• Refractive Index: 1.4760
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 10.10±0.10(Predicted)
• BRN: 1190
• CAS DataBase Reference: N,N-Dimethylpiperidin-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: N,N-Dimethylpiperidin-4-amine(50533-97-6)
• EPA Substance Registry System: N,N-Dimethylpiperidin-4-amine(50533-97-6)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 10-34-22
• Safety Statements: 26-36/37/39-45
• RIDADR: 2734
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 50533-97-6(Hazardous Substances Data)

Usage

Uses

4-(Dimethylamino)piperidine is having molecular features associated with polyamine modulation of N-methyl-D-aspartate receptors. It is utilized as a mechanism for reducing the effects of alcohol dependence.

Synthesis

1-(tert-Butoxycarbonyl)-4-piperidone (998 mg, 4.75 mmol) in methanol (15 mL) was treated with dimethylamine hydrochloride (800 mg, 9.8 mmol) and sodium cyanoborohydride (270 mg, 4.3 mmol) at rt. After 4 days, concentrated HCl (10 mL) was added and volume of the reaction was reduced in vacuo. The resulting residue was dissolved in H2O (30 mL) and treated with a 2M NaOH solution to achieve a pH of 10. The aqueous solution was extracted with methylene chloride (3×20 mL) and the combined organics were dried over Na2SO4 and removed in vacuo. The resulting amine 106 (169 mg).

InChI:InChI=1/C7H16N2/c1-9(2)7-3-5-8-6-4-7/h7-8H,3-6H2,1-2H3

Upstream product

• 1122-58-3 dmap 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 124-40-3 dimethyl amine 
• 64168-08-7 1-benzyl-N,N-dimethylpiperidin-4-amine 
• 506-59-2 N,N-dimethylammonium chloride 

Downstream Products

• 211247-60-8 N,N-dimethyl-1-(4-nitrophenyl)piperidin-4-amine 
• 186429-84-5 5-Chloro-1H-indole-2-carboxylic acid [1-benzyl-2-(4-dimethylamino-piperidin-1-yl)-2-oxo-ethyl]-amide 
• 45584-07-4 (4-piperidyl)methylamine 
• 1121-58-0 4-(Methylamino)pyridine 
• 1122-58-3 dmap 

Relevant articles and documents

CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS

Provided are conjugates of camptothecin analogs with a cell-binding molecule of formula (I), wherein R1, R2, R3, R4, R5, X, L, n, m, T and ----- are defined herein. It also provides methods of making the conjugates of camptothecin analogs to a cell-binding agent, as well as methods of using the conjugates in targeted treatment of cancer, infection, and immunological disorders.

The effect of substitution on the utility of piperidines and octahydroindoles for reversible hydrogen storage

Substituted piperidines and octahydroindoles are compared in terms of their usability as reversible organic hydrogen storage liquids for hydrogen-powered fuel cells. Theoretical Gaussian calculations indicate which structural features are likely to lower the enthalpy of dehydrogenation. Experimental results show that attaching electron donating or conjugated substituents to the piperidine ring greatly increases the rate of catalytic dehydrogenation, with the greatest rates being observed with 4-aminopiperidine and piperidine-4-carboxamide. Undesired side reactions were observed with some compounds such as alkyl transfer reactions during the dehydrogenation of 4-dimethylaminopiperidine, C-O and C-N cleavage reactions during hydrogenation and/or subsequent dehydrogenation of 4-alkoxy and 4-amino indoles, and disproportionation during the hydrogenation of 4-aminopyridine. The Royal Society of Chemistry and the Centre National de la Recherche Scientifique.

Rifamycin analogs and uses thereof

The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3′-hydroxy analogs, 4′- and/or 6′ halo and/or alkoxy analogs, and various 5′ substituents that incorporate a cyclic amine moiety.